SARS-CoV-2 Spike is heavily modified by N-glycosylation (Figure ), and the glycan attachment sites are highly conserved across the different variants of the virus . The abundance of glycans on SARS-CoV-2 Spike, much like the structurally similar HIV-1 Env cell entry protein machine, has inspired the search for possible SARS-CoV-2 therapeutics among lectins previously shown to be effective as HIV-1 infection inhibitors. For example, the mannose-specific lectin griffithsin (GRFT), a known potent HIV-1 inhibitor, has shown antiviral activity against SARS-CoV-2 pseudoviruses and live viruses .